News | March 17, 2009

De Novo Coronary Lesions May Benefit from New Stent Treatment, Study Shows

March 17, 2009 – Twelve-month data from the ATLANTA Trial shows that the CATANIA Coronary Stent System with NanoThin Polyzene-F offers sustained benefit in the treatment of de novo coronary lesions and maximizes endothelialization, while reducing restenosis, thrombogenicity, and the need for long-term dual-antiplatelet therapy.

The CATANIA Stent may be an alternative to both bare metal stents (BMS) and drug-eluting stents (DES). These conclusions were published in the latest issue of the Journal of the American College of Cardiology: Cardiovascular Interventions.

Sponsored by CeloNova BioSciences, manufacturer of the CATANIA stent, the ATLANTA Trial is a first-in-man (FIM), prospective, single center study involving 55 patients treated with the CATANIA Stent for symptomatic ischemic heart disease due to de novo, obstructive lesions of native coronary arteries.

At 12 months, in a reportedly unusually complex FIM patient population, the results showed zero (0.0) percent stent thrombosis, death, myocardial infarction, stroke, or coronary artery bypass graft. Target lesion revascularization was 10.9 percent (only 3.6 percent clinically driven), with a binary restenosis rate of 6.8 percent. All patients stopped dual anti-platelet therapy after 30 days. The procedural success rate was 100 percent.

Independent laboratories analyzed coronary angiography and intravascular ultrasound data for all patients immediately after stent implantation and at 6-months. Analysis of 19,028 struts using optimal coherence tomography in a subset of 15 randomly selected patients revealed complete endothelialization and 99.5 percent stent strut coverage.

"CeloNova has started a scientific revolution involving the way physicians think about BMS and DES. I can definitely assert that Polyzene-F is innovative, effective in several aspects, unique and striking. The 12-month ATLANTA data indicate that the CATANIA stent with Polyzene-F is truly a new and promising class of stent," said Corrado Tamburino, M.D., Ph.D., FESC, FSCAI, FSICI-GISE, professor of cardiology and chief of the cardiovascular department, Ferrarotto Hospital, Catania, Italy, and lead investigator in the ATLANTA Trial.

The rapid-exchange, cobalt-chromium CATANIA stent is currently available for sale in Europe in 60 sizes, in lengths from 8-38mm and in diameters from 2.0-4.0mm. The CATANIA stent surface has a 35-40 nanometer surface treatment of Polyzene-F, an inorganic, biocompatible polymer that is anti-thrombotic, anti-inflammatory, bacterial-resistant, lubricious, and essentially cloaks the device's presence from the body to promote healthy endothelial cell growth without stimulating platelet activation.

For more information: www.celonova.com.

Related Content

The TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

The presentation of the ESC late-breaker TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

News | Stents| November 24, 2017
November 24, 2017 – During a late-breaking session at the European Society of Cardiology (ESC) 2017 meeting, presente
News | Stents| November 10, 2017
Cordis, a Cardinal Health company, recently unveiled a comprehensive interventional cardiology portfolio, which now...
OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

Feature | Stents| November 08, 2017
November 8, 2017 – New results from the HARMONEE Japan/U.S.
FDA Approves COBRA REDUCE Trial of 14-Day DAPT With CeloNova Stent
News | Stents| October 27, 2017
CeloNova BioSciences Inc. announced the U.S. Food and Drug Administration (FDA) approved expansion of CeloNova's...
CeloNova Cobra Pzf stent
Technology | Stents| March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents| January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
EXCEL Trial, TCT 2016, drug-eluting stents, CABG, surgery left main heart disease, LMCAD

Gregg W. Stone, M.D., presenting the EXCEL data at TCT 2016 during a standing room only late-breaking trial session.

Feature | Stents| January 12, 2017 | Dave Fornell
The biggest news from the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting this past fall was the results
Biotronik's Osiro stent, prison IV trial

Biotronik's Osiro ultra-thin strut, sirolimus-eluting stent.

News | Stents| November 09, 2016
November 9, 2016 – Results from a randomized, multicenter trial failed to show non-inferiority of hybrid, ultra-thin
OCT stent strut coverage

OCT imaging showing neointimal tissue coverage of metallic stent struts.

News | Stents| November 07, 2016
November 7, 2016 – Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
biosensors Biofreedom stent
News | Stents| November 07, 2016
November 7, 2016 – The two-year results from LEADERS FREE, the first randomized clinical trial dedicated to high blee
Overlay Init